Skip to main
CSCI

CSCI Earnings Dates & Reports

CSCI Most Recent Earnings

Report Date
Period EndingQ1 2024
Est. EPS-$3.24
Actual EPS-$4.74
EarningsMiss

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

CSCI Earnings per Share (EPS) History

Signup for full access
Browse free

CSCI Latest Earnings

The value each CSCI share was expected to gain vs. the value each share gained.

CSCI reported its most recent earnings on for Q1 2024, posting earnings per share (EPS) of -$4.74. This exceeded analysts' expectations of -$3.24 by 46.30%, marking a Miss.

For comparison, COSCIENS Biopharma Inc reported EPS of -$3.52 in the same quarter last year.

The company is expected to announce its next earnings report on , with analysts projecting an EPS of $0.

CSCI Earnings History

Earnings
Est. EPSActual EPSSurprise
Q3 2025
Q2 2025
-$0.85
DeckReportListen
Q1 2025
-$1.16
DeckReportListen
Q4 2024
-$2.15
DeckReportListen
Q3 2024
-$1.85
DeckReportListen
View all

CSCI Earnings Related Price Changes

Earnings announcements may impact a stock’s price. This table highlights the COSCIENS Biopharma Inc’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.

Report datePrice 1D beforePrice 1D afterChange

CSCI Earnings FAQs

CSCI last reported earnings on May 14, 2024 for Q1 2024, posting an EPS of -$4.74, which Miss the estimate of -$3.24 by 46.30%.

For Q1 2024, CSCI reported an EPS of -$4.74, missing analysts' estimate of -$3.24 by 46.30%.

For Q1 2024, CSCI Miss expectations with an actual EPS of -$4.74 vs. an estimated EPS of -$3.24.

Following the last earnings report on May 14, 2024, CSCI's stock price moved — from — to —.

The next CSCI earnings call is scheduled for Jan. 6, 2026, where executives will discuss financial results and outlook.

COSCIENS Biopharma Inc (CSCI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.